过去一年中添加的文章，按日期排序
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
JS Ju, ACC Huang, PH Tung, CH Huang, TH Chiu… - Scientific Reports, 2023 - nature.com
228 天前 - … In BM patients, gefitinib/erlotinib-treated ones with 19 deletion … NSCLC patients,
in which gefitinib/erlotinib-treated patients presented a shorter PFS compared to afatinib-treated …
in which gefitinib/erlotinib-treated patients presented a shorter PFS compared to afatinib-treated …
[引用][C] Non-Small Cell Lung Cancer Genotype Prediction Utilizing Multiparametric Artificial Intelligence Investigations
S Asadian - Academic Radiology, 2024 - academicradiology.org
229 天前 - … to tyrosine kinase pathway inhibitors (Erlotinib, Gefitinib, Afatinib), KRAS-… patients.
They can provide information for clinicians to establish timely strategies for cancer treatment. …
They can provide information for clinicians to establish timely strategies for cancer treatment. …
Epidermal Growth Factor Receptor Inhibitors for Lung Cancer and the Risk of Keratitis
230 天前 - … Patients aged 18 years or older treated with EGFRis for lung cancer were included
in the exposed group. The EGFRi agents included gefitinib, erlotinib, … gefitinib and erlotinib. …
in the exposed group. The EGFRi agents included gefitinib, erlotinib, … gefitinib and erlotinib. …
A Retrospective and Prospective Study on EGFR Mutations in Lung Carcinomas
Y Pothina, G Vahini, ML Shree, T Asha - 2023 - eprint.subtopublish.com
233 天前 - … institute, together with the patients' responses to targeted therapy and the expression
of … , and twelve patients were put on Gefitinib and Erlotinib targeted therapy. All twelve of …
of … , and twelve patients were put on Gefitinib and Erlotinib targeted therapy. All twelve of …
Treatment outcomes of non-small cell lung cancers treated with EGFR tyrosine kinase inhibitors: a real-world cohort study
O Manninen, L Puuniemi, S Iivanainen, M Arffman… - Acta …, 2023 - Taylor & Francis
242 天前 - … overall survival for the erlotinib users according to time of therapy initiation. There
was … We did not observe any difference in survival of gefitinib treated according to gender. A …
was … We did not observe any difference in survival of gefitinib treated according to gender. A …
Brief Report: Droplet Digital Polymerase Chain Reaction Versus Plasma Next-Generation Sequencing in Detecting Clearance of Plasma EGFR Mutations and …
248 天前 - … of improved survival among patients with advanced EGFR-… treatment options, there
is an urgent need to improve risk stratification to help select patients for combination therapy …
is an urgent need to improve risk stratification to help select patients for combination therapy …
MO35-1 Prognostic evolution of EGFR-mutated non-small cell lung cancer over the past 20 years since the beginning with gefitinib
T Nakagomi, Y Kim, N Sato, R Yokouchi… - Annals of …, 2023 - annalsofoncology.org
248 天前 - … for all patients treated with molecular targeted therapy for … generation (Gefitinib),
2nd generation (Erlotinib, Afatinib), … (MST: Gefitinib=29.2 months, Erlotinib=31.6 months, Afatinib…
2nd generation (Erlotinib, Afatinib), … (MST: Gefitinib=29.2 months, Erlotinib=31.6 months, Afatinib…
O7-2 A phase II study to assess the efficacy of osimertinib in patients with EGFR MT (+) T790M (-) NSCLC
D Hayakawa, M Takeda, M Shimokawa… - Annals of …, 2023 - annalsofoncology.org
248 天前 - … gefitinib and erlotinib, and the secondgeneration EGFR-TKIs, afatinib and dacomitinib,
have been approved for the treat… administered to patients with T790M after treatment with …
have been approved for the treat… administered to patients with T790M after treatment with …
578P Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute …
LJ Hung, JWC Chang, CY Huang, YF Fang… - Annals of …, 2023 - annalsofoncology.org
248 天前 - … , respectively) and erlotinib (10.8 months and 18.5 … , patients treated with afatinib
also experienced more grade ≥3 adverse events than those treated with gefitinib and erlotinib, …
also experienced more grade ≥3 adverse events than those treated with gefitinib and erlotinib, …